Syngene International Limited – FY2025‑26 Results & Dividend

Key Highlights (Year ended 31 Mar 2026)

• Revenue:
  • Standalone: Rs 34,907 mn (↑ 1.4% YoY)
  • Consolidated: Rs 38,094 mn (↑ 1.8% YoY)
• Profit after tax:
  • Standalone: Rs 1,482 mn (↓ 68% YoY)
  • Consolidated: Rs 1,479 mn (↓ 70% YoY)
• Earnings per share (Basic): Rs 3.68 (standalone) vs Rs 7.58 last year; Rs 7.87 (consolidated) vs Rs 12.35 last year.
• Operating cash flow: Rs 9,152 mn (consolidated) – still robust but down from Rs 11,676 mn.
• Cash & cash equivalents: Rs 2,286 mn at year‑end (down from Rs 3,671 mn).
• Dividend: Final dividend of Rs 1.25 per share (record date 26 Jun 2026).
• Governance: New statutory auditors appointed for five years; 33rd AGM scheduled for 29 Jul 2026.

Financial Commentary

• Revenue Growth: Modest increase driven by higher contract research and manufacturing volumes.
• Margin Compression: Higher employee benefits, foreign‑exchange losses, and increased depreciation (due to recent asset acquisitions) pushed expenses up, eroding margins.
• Exceptional Items: Net credit of Rs 229 mn (standalone) and Rs 244 mn (consolidated) from revised labour‑code gratuity calculations; termination benefits of Rs 304 mn added as a one‑off charge.
• Liquidity: Operating cash flow remains positive, but net cash fell due to significant investing outflows (mainly capital expenditures and investment in securities).

Strategic & Regulatory Updates

• Long‑Term Incentive Plan: Allotment of 729,727 shares to the Employees Welfare Trust aligns management incentives with shareholder value.
• Labour Code Impact: Re‑measurement of gratuity obligations reduced exceptional expense, but ongoing regulatory changes could affect future cost structures.
• Audit Change: Appointment of S.R. Batliboi & Associates LLP ensures continuity of audit quality.

Risks & Opportunities

• Risks:
  • Continued pressure on profitability from rising employee costs and foreign‑exchange volatility.
  • Declining cash reserves may limit flexibility for further capex.
  • Potential dilution from equity issuances under incentive plans.
• Opportunities:
  • Expansion of biologics manufacturing capacity (US acquisition) positions the group for higher-margin large‑molecule contracts.
  • Strong cash‑flow generation supports dividend sustainability and future investments.
  • Growing demand for contract research services in the pharma sector.

Outlook

The company shows resilience through revenue growth and cash generation, yet the sharp earnings decline underscores the need for cost‑control and margin improvement. The modest dividend and strategic investments in biologics capacity provide a balanced view, leading to a moderately positive outlook.

Prepared on 29 April 2026 for investors.